Design method of membrane protection peptide and application of membrane protection peptide in cell cryopreservation

By designing membrane protection peptides, using the 11 amino acid repeat sequence of LEA3 protein, a functional peptide material with membrane protection is developed, which solves the problem of cell membrane damage during cryopreservation and significantly improves cell recovery.

CN119409763APending Publication Date: 2025-02-11TECHNICAL INST OF PHYSICS & CHEMISTRY - CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411302162.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2025-02-11

AI Technical Summary

Technical Problem

During cryopreservation, the cell membrane is easily damaged, resulting in cell damage, and the prior art is difficult to effectively protect the cell membrane.

Method used

By designing membrane protection peptides, using the 11 amino acid repeat sequences of LEA3 protein, the sequence with an α helical structure was screened through the construction of a phylogenetic tree, clustering analysis and conservative analysis, and functional peptide materials with membrane protection were developed.

Benefits of technology

It successfully improved the fluidity of the cell membrane at low temperatures and significantly improved the cell recovery rate. In particular, ARE peptides increased the cell recovery rate from 16% to 68% in the cryoprotection of rat erythrocytes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119409763A_ABST
    Figure CN119409763A_ABST
Patent Text Reader

Abstract

The invention provides a design method of a membrane protection peptide, develops a series of functional polypeptide materials with a membrane protection effect and successfully applies the functional polypeptide materials to cryopreservation of cells. Biocompatibility detection shows that the designed membrane protection peptide has good cell compatibility and can be applied to cell cryopreservation, and the cell recovery rate can be increased from 16% to 68% through the sequence with the optimal effect. The membrane protection peptide provided by the invention shows good potential of being applied to cell cryopreservation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and mainly relates to a design method of a membrane protective peptide and a series of functional polypeptide materials with membrane protective effects developed by the method, which can be effectively applied to the cryopreservation of cells. Background Art

[0002] Cryopreservation is a widely used technology that enables long-term storage of cells. It can suspend cell metabolism, thereby achieving indefinite long-term storage of cells. However, during the cryopreservation process, the reduction of cell physiological metabolism and the formation of ice crystals can cause cell damage, such as enzyme inactivation, oxidative damage, and membrane damage. Among them, membrane rupture is one of the most important damages. Therefore, the development of efficient membrane protection materials is very important for cell cryopreservation.

[0003] Late embryogenesis abundant (LEA) proteins are a class of stress resistance proteins found in plants, animals and microorganisms. They can help the host resist adversities such as low temperature, high salt or drought, and protect the host from damage caused by adversity. This type of protein can be divided into 7 groups according to its primary sequence. Among them, the primary sequence feature of the third group of LEA proteins (LEA3) is that it contains 11 amino acid repeats. Researchers predicted its structure and found that these 11 amino acid repeats are similar to the type A amphipathic helical structure in various plasma apolipoproteins. The type A amphipathic helical structure has been proven to increase the fluidity of the cell membrane by directly interacting with the cell membrane, thereby better maintaining the integrity of the cell membrane under adversity. The similarity between LEA3 protein and type A amphipathic helical structure also makes researchers believe that LEA3 protein can also protect the cell membrane from damage under adversity in a similar way. However, LEA3 protein is an inherently disordered protein and is easily degraded. And when it performs its function, it needs to be induced from a disordered structure to an α-helical structure, but the current technology for inducing the formation of an α-helical structure is still difficult and challenging in practical applications. Compared to intact proteins, peptides generally have simpler and more stable structures. They are also generally less immunogenic and more editable than intact proteins. Summary of the invention

[0004] In order to improve the above technical problems, the present invention provides a design method for membrane protective peptides and develops a series of functional polypeptide materials with membrane protective effects. The mechanism of membrane protective peptides is further analyzed and successfully applied to cell cryopreservation.

[0005] In one aspect, the present invention provides a method for designing a membrane protective peptide, characterized in that it comprises the following steps:

[0006] (1) Obtaining the LEA3 protein sequence;

[0007] (2) performing cluster analysis on the obtained LEA3 proteins by constructing a phylogenetic tree, and grouping the sequences with higher sequence similarity into one group according to the topological structure of the phylogenetic tree;

[0008] (3) extracting the repeated sequences with the same sequence motif in the group, performing conservation analysis on them, and screening out the sequences with α-helical structure.

[0009] In one embodiment, the LEA3 protein sequence is obtained by downloading all LEA protein sequences by species (including animal, plant, protists, virus, fungi and bacteria) from the NCBI database, discarding sequences containing the words "partial", "predicted", "precursor", "LOW QUALITY", "hypothetical" and "putative", and then using Decrease redundancy (https: / / web.expasy.org / decrease_redundancy / ) software to deduplicate the sequences, and further extracting the LEA3 protein sequence using MEME software (http: / / meme-suite.org / tools / meme).

[0010] In one embodiment, MEME software (http: / / meme-suite.org / tools / meme) is used to extract repetitive sequences with the same sequence motif in each group of LEA3 proteins, and the repetitive sequences are subjected to conservation analysis using weblogo software (http: / / weblogo.berkeley.edu / logo.cgi), and the repetitive sequences are further predicted using pepfold software (http: / / bioserv.rpbs.univ-paris-diderot.fr / PEP-FOLD) to find sequences with α-helical structures.

[0011] In another aspect, the present invention provides a membrane protective peptide designed by the aforementioned method.

[0012] In one embodiment, the amino acid sequence of the membrane protective peptide is shown in any one of SEQ ID: 1-12.

[0013] In one embodiment, the amino acid sequence of the membrane protective peptide is as shown in any one of SEQ ID: 1, 11 and 12;

[0014] More preferably, the amino acid sequence of the membrane protective peptide is as shown in SEQ ID: 1.

[0015] In another aspect, the present invention provides a composition comprising the membrane protective peptide of claim 4 at a concentration of 0-10 mM and a cell protective agent at a concentration of 200 mM-700 mM.

[0016] In some embodiments, the cell protectant is selected from one or more of betaine, glycerol, dimethyl sulfoxide (DMSO), ethylene glycol, polyvinyl pyrrolidone (PVP), sucrose, dextran, albumin, hydroxyethyl starch (HES), proline and glycine.

[0017] In some embodiments, the amino acid sequence of the membrane protective peptide is as shown in any one of SEQ ID: 1, 11 and 12, and the cell protective agent is betaine at a concentration of 200 mM.

[0018] In some embodiments, the amino acid sequence of the membrane protective peptide is as shown in any one of SEQ ID: 1, 11 and 12, and the cell protective agent is betaine at a concentration of 300 mM.

[0019] In some embodiments, the amino acid sequence of the membrane protective peptide is as shown in any one of SEQ ID: 1, 11 and 12, and the cell protectant is betaine at a concentration of 700 mM.

[0020] In another aspect, the present invention provides use of the aforementioned membrane protective peptide and the aforementioned composition in the preparation of a medicament for cell cryopreservation.

[0021] Beneficial Effects

[0022] The present invention provides a method for designing membrane protective peptides, and 10 membrane protective peptides capable of maintaining cell membrane fluidity at low temperatures were developed and designed by this method. Further mechanism analysis of the AKE polypeptide with the best effect revealed that it mainly interacted with the cell membrane through electrostatic interaction. Through biocompatibility testing, it was found that the three polypeptides ARE, AKE and AGE all had good cell compatibility. When applied to cell cryopreservation, the three polypeptides can effectively improve the cell recovery rate. Among them, the ARE polypeptide with the best effect can increase the cell recovery rate from 16% to 68% when applied to the cryoprotection of rat red blood cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 It is a sequence design flow chart.

[0024] Figure 2 Clustering is performed through evolutionary trees.

[0025] Figure 3These are 13 potential membrane-protective peptides obtained through conservation analysis.

[0026] Figure 4 These are the structures predicted for 13 peptides using the Pepfold software.

[0027] Figure 5 This is the result of further experimental verification of 10 predicted peptides with α-helical structure using circular dichroism spectroscopy.

[0028] Figure 6 The phase transition temperature test results of 10 peptides with α-helical structure, where a is the phase transition temperature of liposomes from gel phase to liquid crystal phase after different peptides are mixed with DOPE;

[0029] b is the enthalpy change of liposomes from gel phase to liquid crystal phase after different peptides were mixed with DOPE;

[0030] c is the phase transition temperature of the liposome from the gel phase to the liquid crystal phase after different peptides were mixed with DOPC;

[0031] d is the enthalpy change of liposomes from gel phase to liquid crystal phase after different peptides were mixed with DOPC.

[0032] Figure 7 is the effect of different peptides on the fluidity of erythrocyte membrane, ai is the fluorescence spectra of pyrene probe formed at 4℃ to 37℃ when erythrocytes were incubated with control group and 10 peptides respectively; m is the I of different peptides at 4℃ D / I M The ratio was minus the I of the PBS control group at 37°C. D / I M Ratio, I of PBS control group at 4℃ D / I M The value is minus the I at 37°C D / I M The ratio is shown on the far left of the figure, △I D / I M A decrease means an increase in cell mobility.

[0033] Figure 8 The figure is a schematic diagram of the effects of the three membrane-protective peptides ARE, AKE and AGE on the cell membrane, where a is the sequence of three different membrane-protective peptides;

[0034] bc is the roughness of the red blood cell surface after the three membrane protection peptides were incubated with red blood cells by AFM;

[0035] d is the phase transition temperature of liposomes after the three membrane protection peptides ARE, AKE and AGE were mixed with 40mM DOPE at 10mM respectively;

[0036] e is the phase transition temperature of liposomes after the three membrane protection peptides ARE, AKE and AGE were mixed with 40 mM DOPC at 10 mM respectively;

[0037] f is the cell membrane fluidity of sheep erythrocytes under the influence of three membrane protective peptides, ARE, AKE and AGE, at 4°C minus the cell membrane fluidity of erythrocytes without membrane protective peptides at 37°C;

[0038] g is the changes in cell membrane fluidity at different temperature points of fresh sheep erythrocytes (control group), sheep erythrocytes incubated with ARE membrane protective peptide (ARE group) and sheep erythrocytes washed after incubation with ARE membrane protective peptide (recovered cell group).

[0039] Fig. 9 These are the results of biocompatibility testing of three membrane-protecting peptides on pigs, sheep and rats.

[0040] Fig.10 Where ac is the cell recovery rate of pig, sheep and rat red blood cells after cryopreservation protection with cryopreservation protection solution. DETAILED DESCRIPTION

[0041] Experimental materials and reagents:

[0042] The polypeptides used in the present invention were synthesized by Hefei Guopeptide Biotechnology Co., Ltd. The experimental reagents were all commonly used molecular biology reagents. The red blood cells used were purchased from Solebol.

[0043] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0044] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0045] Example 1: Design and verification of membrane protective peptides

[0046] The overall design process of membrane protective peptides is as follows Figure 1 shown.

[0047] 1.1 Acquisition of LEA3 protein sequence

[0048] All LEA protein sequences were downloaded from the NCBI database by species (including animal, plant, protists, virus, fungi and bacteria), and the sequences containing the words "partial", "predicted", "precursor", "LOWQUALITY", "hypothetical" and "putative" were discarded. Then, the sequences were de-redundanted using the software Decreaseredundancy (https: / / web.expasy.org / decrease_redundancy / ), and the LEA3 protein sequence was further extracted using the software MEME (http: / / meme-suite.org / tools / meme).

[0049] 1.2 Design of membrane protective peptides

[0050] The obtained LEA3 proteins were clustered by constructing a phylogenetic tree (e.g. Figure 2 ), and the sequences with higher sequence similarity were grouped together according to the topological structure of the obtained evolutionary tree. Then, MEME software (http: / / meme-suite.org / tools / meme) was used to search for 11 amino acid repeats with the same sequence motif in each group of LEA3 proteins, and they were extracted and analyzed for conservation using weblogo software (http: / / weblogo.berkeley.edu / logo.cgi). Figure 3 Finally, 13 potential membrane protective peptides were obtained. The pepfold software (http: / / bioserv.rpbs.univ-paris-diderot.fr / PEP-FOLD) was used to predict the structures of these 13 sequences (as shown in Figure 4 As shown in Table 1, 10 sequences with α-helical structure were found.

[0051] Table 1 Amino acid sequences of the 10 peptides screened and their solubility in PBS

[0052]

[0053] 1.3 Circular dichroism detection

[0054] The 10 potential membrane protective peptides with α-helical structures were synthesized and dissolved in PBS to form a 1 mg / mL peptide solution. Then, a J-1700 circular dichroism spectrometer was used for detection. The wavelength range was set to 190-260 nm with a wavelength interval of 1 nm. Each sample was repeated 3 times. Afterwards, the secondary structure of the results was analyzed using the BeStSel online website (http: / / bestsel.elte.hu) to further verify that the 10 sequences selected had an α-helical structure (the results are shown in Figure 2). Figure 5 shown).

[0055] 1.4 Phase change temperature detection

[0056] First, DOPE and DOPC were dissolved in ethanol respectively to form a liposome solution with a final concentration of 40mM. They were placed in a rotary evaporator respectively to gradually form a thin film on the tube wall during the drying process. The film was then hydrated with PBS buffer and repeatedly passed through a 200nm filter membrane using a syringe to finally form liposomes with a diameter of 200nm. Secondly, the 1mg / mL of the above-mentioned polypeptide solution in 1.3 was mixed with liposome DOPE or DOPC, and its phase transition temperature was detected by DSC. Before each test, 10μL of the solution was placed in a crucible, kept at 20℃ for 2min, then cooled to -40℃ at 10℃ / min, equilibrated for 2min, and then heated at 2.5℃ / min. The heat flow curve during the heating process was recorded, and the phase transition temperature and enthalpy change of the liposome from the gel phase to the liquid crystal phase were obtained. Each sample was repeated 3 times, and the final result was averaged. The results are as follows Figure 6 As shown, the 10 designed polypeptides can reduce the phase transition temperature of liposomes to varying degrees, among which the polypeptide named AKE has the best effect.

[0057] 1.5 Cell membrane fluidity detection

[0058] This application uses pyrene probe to detect cell membrane fluidity. 7 / mL red blood cells were dissolved in PBS containing different peptides, and a pyrene probe with a final concentration of 15mM was added. The PBS group was used as a negative control. After incubation at different temperatures for 30min, a multifunctional microplate reader was used for detection. The excitation light was set to 339nm, and the emission light range was set to 350-600nm. By detecting 391nm (I M ) and 465nm(I D ) at the point where the fluorescence value is calculated by D / I M The ratio of 2 and 4 gives the cell membrane fluidity. Figure 7 As shown, the 10 screened peptides can improve the fluidity of cell membrane at low temperature to a certain extent, among which AKE has the best effect.

[0059] 1.6 Cell membrane action mechanism detection

[0060] The present invention further studies the mechanism of AKE. The positively charged lysine K in its sequence is mutated into arginine R with stronger positive charge and glycine G with no charge, named ARE and AGE, respectively, so that the positive charge is: ARE>AKE>AGE.

[0061] Table 2 Amino acid sequences of membrane protective peptides AKE, ARE and AGE and their solubility in PBS

[0062]

[0063]

[0064] First, the peptides AKE, ARE and AGE in Table 2 were synthesized, and then the synthesized peptides were dissolved in PBS to form a 1 mg / mL corresponding peptide solution. The red blood cells were incubated with 1 mg / mL of the aforementioned peptide solution at 4°C for 12 hours. The glass slide was modified with polylysine, and then 50 μL of the incubated red blood cells were added to the glass slide and allowed to dry naturally. Subsequently, it was fixed with 1% glutaraldehyde at room temperature for 10 minutes. Subsequently, the sample was washed 3 times with PBS and air-dried. The surface of the red blood cells was scanned using an atomic force microscope (AFM), and the scanning scale was set to 500nm×500nm. The image was analyzed using Gwyddion 2.43 software. The results are shown in Figure 2. Figure 8 As shown in Figure 2, AFM detection, with PBS as a control, found that incubation with red blood cells, these three peptides can cause cell membrane wrinkles, indicating that there is an interaction between the peptides and the cell membrane. ARE has the most obvious effect on the change of cell membrane roughness, followed by AKE, and AGE has the weakest effect (e.g. Figure 8 bc). In addition, these three peptides can effectively reduce the phase transition temperature of liposomes. At a concentration of 10mM, ARE, AKE and AGE can reduce the phase transition temperature of DOPE by 4.28℃, 2.10℃ and 1.51℃, and the phase transition temperature of DOPC by 5.22℃, 3.22℃ and 2.41℃ respectively (as shown in Figure 2). Figure 8 Finally, incubation with PBS (control group) and the three peptides improved the membrane fluidity of red blood cells at 4°C. Among them, the membrane fluidity of ARE was even better than that of the control group at 37°C, while AKE was the same as the control group at 4°C. Although AGE was improved, it was still lower than the fluidity of the control group at 37°C (as shown in Figure 2). Figure 8 f).

[0065] In summary, ARE can produce stronger interactions with cell membranes, thereby better reducing the phase transition temperature of liposomes and maintaining the fluidity of cell membranes at low temperatures. Therefore, it can be inferred that AKE and cell membranes mainly affect the reduction of phase transition temperature and maintenance of cell membrane fluidity at low temperatures through electrostatic interactions.

[0066] 1.7. Biocompatibility testing

[0067] Place the purchased red blood cells in a centrifuge tube, centrifuge at 717g for 5 minutes, then discard the supernatant, add PBS and wash twice until the washing solution is clear for use. Prepare AKE, ARE and AGE polypeptides with PBS to a concentration of 10 mg / mL. After that, take 10μL of red blood cell sediment in a PCR tube, add 90μL PBS and mix well, and place in a 37℃ incubator containing 5% CO2 for incubation for 30 minutes. Take it out, centrifuge at 717g for 5 minutes, and take a picture of the sample. Take 20μL of supernatant and place it in a 96-well plate to which 80μL PBS has been added, mix well, and use a multifunctional microplate reader to measure its absorbance at 541nm and record it as As. Red blood cells diluted 5 times with ultrapure water and PBS were used as negative and positive controls, respectively, and their absorbances were measured and recorded as An and Ap. The hemolysis rate of each sample was calculated according to the following formula:

[0068]

[0069] Among them, As represents the absorbance of the sample, Ap represents the absorbance of the positive control, and An represents the absorbance of the negative control.

[0070] like Fig. 9 As shown, after the three polypeptides ARE, AKE and AGE were incubated with red blood cells of pigs, sheep and rats, they all had good biocompatibility and the hemolysis rate did not exceed 1%.

[0071] Example 2: Application of membrane protective peptides in cell cryopreservation

[0072] Preparation of cryopreservation solution

[0073] The present invention relates to the freezing of three types of red blood cells. For pig, sheep and rat red blood cells, the freezing solution uses 200mM, 300mM and 700mM betaine respectively, and is mixed with the three polypeptides ARE, AKE and AGE at a concentration of 0-10mM respectively, and the pH is adjusted to 7.0 to form the final cell freezing preservation solution. For pig red blood cells, the freezing solution uses 200mM betaine and is mixed with the three membrane protective peptides ARE, AKE and AGE at a concentration of 0-10mM respectively. For sheep red blood cells, the freezing solution uses 300mM betaine and is mixed with the three membrane protective peptides ARE, AKE and AGE at a concentration of 0-10mM respectively. For rat red blood cells, the freezing solution uses 700mM betaine and is mixed with the three membrane protective peptides ARE, AKE and AGE at a concentration of 0-10mM respectively.

[0074] Red blood cell cryopreservation experiment

[0075] Mix 1 mL of cryopreservation solution with red blood cells to make the final concentration of red blood cells 4%. Then, directly put it into liquid nitrogen, take it out after freezing for a period of time, and place it in a 45°C water bath for recovery. After the cells are completely dissolved, centrifuge at 717g for 5 minutes. Use a multifunctional microplate reader to detect the absorbance of the supernatant. The cell recovery rate is calculated according to the following formula:

[0076]

[0077] like Fig.10 As shown in the figure, the three peptides ARE, AKE and AGE can effectively improve the cryoprotection efficiency of cells. Among them, ARE has the most obvious effect, which can increase the cell recovery rate of rat red blood cells from 16% to 68%.

[0078] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for designing a membrane protective peptide, characterized in that: It includes the following steps: (1) Obtaining the LEA3 protein sequence; (2) performing cluster analysis on the obtained LEA3 proteins by constructing a phylogenetic tree, and grouping the sequences with higher sequence similarity into one group according to the topological structure of the phylogenetic tree; (3) extracting the repeated sequences with the same sequence motif in the group, performing conservation analysis on them, and screening out the sequences with α-helical structure.

2. According to the method of claim 1, the method of obtaining the LEA3 protein sequence is to download all LEA protein sequences by species (including animal, plant, protists, virus, fungi and bacteria) from the NCBI database, discard the sequences containing the words "partial", "predicted", "precursor", "LOW QUALITY", "hypothetical" and "putative", and then use Decrease redundancy (https: / / web.expasy.org / decrease_redundancy / ) software to deduplicate the sequences, and further extract the LEA3 protein sequence using MEME software (http: / / meme-suite.org / tools / meme).

3. The method according to claim 1 or 2, wherein MEME software (http: / / meme-suite.org / tools / meme) is used to extract the repetitive sequences with the same sequence motif in each group of LEA3 proteins, and the conservation analysis of the repetitive sequences is performed using weblogo software (http: / / weblogo.berkeley.edu / logo.cgi), and the structure of the repetitive sequences is further predicted using pepfold software (http: / / bioserv.rpbs.univ-paris-diderot.fr / PEP-FOLD) to find the sequences with α-helical structure.

4. A membrane protective peptide designed and obtained according to the method of any one of claims 1 to 3.

5. The membrane protective peptide according to claim 4, wherein the amino acid sequence of the membrane protective peptide is shown in any one of SEQ ID: 1-12; Preferably, the amino acid sequence of the membrane protective peptide is as shown in SEQ ID:

1.

6. A composition comprising the membrane protective peptide of claim 4 at a concentration of 0-10 mM and a cell protectant at a concentration of 200 mM-700 mM, wherein the cell protectant is selected from one or more of betaine, glycerol, dimethyl sulfoxide (DMSO), ethylene glycol, polyvinyl pyrrolidone (PVP), sucrose, dextran, albumin, hydroxyethyl starch (HES), proline and glycine.

7. The composition according to claim 6, wherein the amino acid sequence of the membrane protective peptide is as shown in any one of SEQ ID: 1, 11 and 12, and the cell protective agent is betaine at a concentration of 200 mM.

8. The composition according to claim 6, wherein the amino acid sequence of the membrane protective peptide is as shown in any one of SEQ ID: 1, 11 and 12, and the cell protective agent is betaine at a concentration of 300 mM.

9. The composition according to claim 6, wherein the amino acid sequence of the membrane protective peptide is as shown in any one of SEQ ID: 1, 11 and 12, and the cell protective agent is betaine at a concentration of 700 mM.

10. Use of the membrane protective peptide according to claim 4 or 5 and the composition according to any one of claims 7 to 9 in the preparation of a medicament for cell cryopreservation.